On the stock market since 2021, it operates in the world of health and science. It has 5,800 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Revenue is spread across several lines; no single product carries the company.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 3 years, sales grew about 15% a year on average.
The company sells $1.2B a year; the problem isn’t sales — it’s costs running above that number.
The average analyst price target is $20.00 — 99% above today’s price.
A loss of $19.4M against $1.2B in annual sales.
At the current pace of spending, the cash lasts about 1 year. After that, the company needs to find new money.
Over the last 12 months, executives reported 127 sells against just 25 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, AGTI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: AGTI has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.